Trial · NCT01857063
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of Exposure | Baseline and after 3 hours of pollen exposure on Day 7 of each treatment period | The Full Analysis Set (FAS) population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Percentage of Participants Who Experience at Least One Adverse Event | Up to 5 weeks | The All Patients as Treated (APaT) population consisted of all randomized participants who received at least one dose of study drug. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Weighted TNSS Averaged During 3 Hours of Exposure | Baseline and after 3 hours of pollen exposure on Day 7 of each treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Nasal Congestion Score Averaged During 3 Hours of Exposure | Baseline and after 3 hours of pollen exposure on Day 7 of each treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Nasal Discharge Score Averaged During 3 Hours of Exposure | Baseline and after 3 hours of pollen exposure on Day 7 of each treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Sneezing Score Averaged During 3 Hours of Exposure | Baseline and after 3 hours of pollen exposure on Day 7 of each treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Baseline and at 30, 60, 90, 120, 150 and 180 minutes after entering chamber room on Day 7 of a treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Weighted TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Baseline and at 30, 60, 90, 120, 150 and 180 minutes after entering chamber room on Day 7 of a treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Nasal Congestion Score at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Baseline and at 30, 60, 90, 120, 150 and 180 minutes after entering chamber room on Day 7 of a treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Nasal Discharge Score at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Baseline and at 30, 60, 90, 120, 150 and 180 minutes after entering chamber room on Day 7 of a treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Sneezing Score at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Baseline and at 30, 60, 90, 120, 150 and 180 minutes after entering chamber room on Day 7 of a treatment period | The FAS population consisted of all randomized participants who took at least one dose of study drug, and had a baseline assessment and at least one post-baseline assessment in a treatment period. | score on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01857063/outcomes